These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32726914)

  • 1. Bitter Melon (
    Sur S; Ray RB
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse roles of bitter melon (
    Sur S; Ray RB
    J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34765739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bitter melon: a panacea for inflammation and cancer.
    Dandawate PR; Subramaniam D; Padhye SB; Anant S
    Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Bortolotti M; Mercatelli D; Polito L
    Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats.
    Sun K; Ding M; Fu C; Li P; Li T; Fang L; Xu J; Zhao Y
    J Ethnopharmacol; 2023 Apr; 306():116154. PubMed ID: 36634725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Antitumor Activities of the Bitter Melon (Momordica charantia).
    Fang EF; Froetscher L; Scheibye-Knudsen M; Bohr VA; Wong JH; Ng TB
    Curr Protein Pept Sci; 2019; 20(3):296-301. PubMed ID: 29932035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
    Raina K; Kumar D; Agarwal R
    Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
    Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
    Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Draft genome sequence of bitter gourd (Momordica charantia), a vegetable and medicinal plant in tropical and subtropical regions.
    Urasaki N; Takagi H; Natsume S; Uemura A; Taniai N; Miyagi N; Fukushima M; Suzuki S; Tarora K; Tamaki M; Sakamoto M; Terauchi R; Matsumura H
    DNA Res; 2017 Feb; 24(1):51-58. PubMed ID: 28028039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
    Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
    Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Çiçek SS
    Front Pharmacol; 2022; 13():904643. PubMed ID: 35656300
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative determination of cucurbitane-type triterpenes and triterpene glycosides in dietary supplements containing bitter melon (Momordica charantia) by HPLC-MS/MS.
    Ma J; Krynitsky AJ; Grundel E; Rader JI
    J AOAC Int; 2012; 95(6):1597-608. PubMed ID: 23451374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitter melon: antagonist to cancer.
    Nerurkar P; Ray RB
    Pharm Res; 2010 Jun; 27(6):1049-53. PubMed ID: 20198408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (Trigonella foenum-graecum) seeds and bitter melon (Momordica charantia) fruit.
    Kenny O; Smyth TJ; Hewage CM; Brunton NP
    Food Chem; 2013 Dec; 141(4):4295-302. PubMed ID: 23993618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolite profiling and in vitro biological activities of two commercial bitter melon (Momordica charantia Linn.) cultivars.
    Perez JL; Jayaprakasha GK; Patil BS
    Food Chem; 2019 Aug; 288():178-186. PubMed ID: 30902279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the bioactive polysaccharides, proteins, and triterpenoids isolated from bitter melon (Momordica charantia) and their relevance for nutraceutical and food application: A review.
    Bora AFM; Kouame KJE; Li X; Liu L; Pan Y
    Int J Biol Macromol; 2023 Mar; 231():123173. PubMed ID: 36642359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
    Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
    Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
    Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
    Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats.
    Shih CC; Lin CH; Lin WL; Wu JB
    J Ethnopharmacol; 2009 May; 123(1):82-90. PubMed ID: 19429344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Report of Pseudoperonospora cubensis Causing Downy Mildew on Momordica balsamina and M. charantia in North Carolina.
    Wallace E; Adams M; Ivors K; Ojiambo PS; Quesada-Ocampo LM
    Plant Dis; 2014 Sep; 98(9):1279. PubMed ID: 30699625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.